Rebate Relief: Incentivizing New Uses for Existing Drugs
This law creates financial incentives for pharmaceutical companies to research new uses for drugs that have been on the market for at least 10 years. The change aims to accelerate access to new treatments for diseases that currently lack approved medication, especially those common among federal program beneficiaries (Medicare/Medicaid). This could lead to faster availability of treatments for previously unmet medical needs.
Key points
Establishes a new category called "Priority Research Drugs" (PRDs) for older drugs being studied for critical new indications.
Modifies how manufacturer rebates are calculated for these specific drugs under Medicare and Medicaid, reducing the financial burden on companies conducting research.
The goal is to encourage the rapid development of treatments for significant unmet medical needs, particularly benefiting patients covered by federal health programs.
Expired
Citizen Poll